RoslinCT, as one of the first in the world to produce clinical-grade human pluripotent stem cells, has a strong focus on science and innovation. In collaboration with Vertex Pharmaceuticals, RoslinCT developed, from early process development through commercialization, the First CRISPR-Edited Cell Therapy Product, exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.
Following the world-breaking first cloning of a mammal (Dolly the Sheep) at the Roslin Institute within the University of Edinburgh (UK) in 1997, there was worldwide interest to access Roslin’s technology and expertise. RoslinCT was established in 2006 to translate this cutting-edge science and apply it to the development of human medicines.
To save the lives of patients by empowering our partners to efficiently progress cell & gene therapies from development to commercialization, as their advanced CDMO partner of choice.